anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Somatic element or prosthesis, made by the cutting and machining of monocrystalline sapphire ceramic (alpha-alumina or corundum) to obtain the desired shape. The sharp edges, burrs and/or scratches are then removed by polishing, to obtain a bending strength of 9000-20,000 kg/cm2. The element pref. has a blade-, peg- or screw-shape so it can form an endostic implant in dental- or orthopaedic surgery. Polishing pref. consists of (a) chemical polishing at high temp. using molten salt, esp. a borate, molybdate, tungstate, V2O5, lead oxide, Na2CO3 or K2CO3; and/or (b) fire polishing at 1200-1900 degrees C, esp. at 1500-1700 degrees C in a reducing atmos. The element is inert to body tissue and fluids, and is much stronger than polycrystalline alumina due to the absence of grain boundaries; and polishing increases the strength of the implant.
This report describes the case of a 62-year-old male patient in Saudi Arabia who developed a diverticular pouch in his oral cavity. Diverticula are rare conditions that appear as protrusions or pouches within the digestive tract's inner lining. The condition can occur in different parts of the digestive system, but the colon is the most affected part. As part of the patient's symptoms, he presented with dysphagia, weight loss, and globus sensations. Multiple diagnostic tests, including ultrasound, computerized tomography (CT), and magnetic resonance imaging (MRI), did not identify the diverticula. Barium and upper gastrointestinal studies were the diagnostic tests that provided accurate diagnoses where several diverticula were discovered during the videofluoroscopic swallow study (VFSS) and fiberoptic endoscopic evaluation of swallowing (FEES). Surgical intervention was recommended by the multidisciplinary team; however, the patient rejected this treatment option. This report highlights the necessity for instrumental swallowing diagnostic evaluation in the workup of the infrequent etiologies of dysphagia and suggests a gap in the current knowledge, prompting further studies on the etiology, incidence, and optimum management of upper gastrointestinal (GI) tract diverticular disease.
Intervention: A total of 88 non-cavitated proximal carious lesions treated with light curable resin modified glass ionomer varnish (Vanish™ XT Extended Contact Varnish, 3M ESPE, St. Paul, MN, U.S.A.) at initial and six-months follow-up visits. In addition to, standard-of-care preventive measures, applied at initial, six-months follow-up, and 12-months follow-up visits.
This proposal is designed to address the increase in drug use among adolescent athletes by studying a school-based version of the random, no-advance warning drug testing program used by the United States Olympic Committee (USOC). High school athletes are a large group, comprising 50% of their school's enrollment. They have a high rate of substance abuse behaviors similar to the general school population, and an even higher use of 'ergrogenic' (athletic enhancing) drugs. Recognizing the high rate of substance abuse among young athletes and their 'role model' effect on other students, the U.S. Supreme Court recently upheld an Oregon School Districts' policy to randomly drug test students engaged in school-sponsored sports. Drug testing has the potential to deter adolescent substance abuse. It is gender-neutral, without ethnic bias and provides a potentially powerful environmental influence. However, despite its legality and theorized effectiveness, schools are implementing drug surveillance without the benefit of randomized, prospective efficacy research.

Focusing on adolescent athletes provides a unique opportunity to study the prevention effect of drug testing. All sports teams in 24 schools who agree to implement mandatory testing as school policy but have never implemented this policy, will be randomly assigned by school, to three years of either: 1) random, no-advance warning drug testing or 2) a 3-year control period without testing. Selection of students for drug testing will be random, with no exclusions for having been previously tested. State-of-the-art testing will include physician specimen collectors under the direction of research physicians (PI \& Co-I), who are Certified USOC Drug Surveillance Crew Chiefs, with specimen analysis at the UCLA Olympic Laboratory using the most accurate analytical techniques to minimize false negative (reducing policy integrity) and false positive (mislabeling students) results. Confidential questionnaires will be completed by student-athletes twice yearly to assess risk and protective factors for drug use and assess self-reported substance abuse. The role model effect of the surveillance program on nonathletes' drug use will be assessed twice yearly by anonymous survey. We will determine the effect of drug testing policy on: 1) adolescent drug use mediators, 2) actual drug use behaviors of student-athletes and their non-athlete peers, and 3) potential gender and demographic differences. Reliability of subjective questionnaire responses will be assessed by comparisons with objective drug test results. Study findings will assist school districts and education agencies evaluate, guide, and implement future drug prevention policy decisions.
The invention belongs to the biotechnology and the medical field and discloses a new human epididymal specific expression sperm binding protein HEL-200 as well as preparation and application thereof. The invention discloses an amino acid sequence of the HEL-200 protein and provides a recombinant expression vector which carries a DNA sequence used for encoding the protein. The invention also discloses a preparation method of the protein and a method for detecting the biological functions of the HEL-200 protein. The protein is located at the back part of the head of a sperm and the tail middle section of the sperm and has low abundance expression in an epididymis, a testis and a liver, and a band of about 35 KD is detected in the epididymis by using western blot. The HEL-200 protein can be used as a target protein or developing an immunological contraceptive and clinically diagnosing and treating male infertility. A method for detecting a corresponding gene or protein based on development of the HEL-200 protein can be widely used for the research field of reproductive medicine.
The invention relates to the technical fields of disinfection, instruments and medicines, in particular to a cleaning solution for flushing wound surfaces under pressure and a preparation method thereof. The cleaning solution for the wound surface under pressure has the effects of efficient bacteriostasis, sterilization, analgesia and local hemostasis, and can be sprayed out at a certain flow rate through a special device to flush the wound surface, and the spraying force of the cleaning solution can be adjusted. The invention solves the problems that the cleaning solution lacks power, can only partially wet and is difficult to clean pollutants, exudates or blood crust adhered to the wound surface during the conventional wound cleaning. The wound cleaning liquid comprises the following components in parts by weight: 0.6-0.9% of osmotic pressure regulator, 0-3% of disinfectant, 0-2% of hemostatic agent, 0-2% of analgesic agent and 94.1-99.1% of medical purified water. The wound cleaning liquid can be combined with the propellant, and is filled into primary or secondary aerosol, or is directly filled into a spray bottle to be filled into spray, and the purposes of spraying the wound cleaning liquid with specific power and flushing the wound can be achieved in both modes. The aerosol or spray of the cleaning liquid for flushing wound surface under pressure is used for filling, sterilizing and packing the wound surface after a specific process, and is formed into a disposable cleaning liquid product for flushing and cleaning superficial wound surface.
The invention discloses an amphiphilic fluorescent carbon dot and a preparation method thereof. The method takes alkyl glycoside as a carbon source and ethylenediamine as a nitrogen source, and selects different solvents to heat to obtain amphiphilic carbon dots with different fluorescence characteristics. The technical problems of low carbon dot cell-entering efficiency and poor cell development effect in biological imaging application are solved. The surfaces of the amphiphilic fluorescent carbon dots simultaneously have hydrophilic groups and lipophilic groups, wherein the hydrophilic groups are amino groups, amide groups and hydroxyl groups; the lipophilic group is alkyl or alkylene. The carbon dots have good stability and solubility in polar solvents and nonpolar solvents, and can show different fluorescence characteristics when dissolved in different solvents. The method has the advantages of cheap and green raw materials and simple and mild process, and the prepared fluorescent carbon dots can be applied to the fields of biological imaging, drug carriers and the like.
PURPOSE OF REVIEW: Noncompressible torso hemorrhage (NCTH) is now considered as the major cause of preventable death after both severe military and civilian trauma. Around 20% of all trauma patients still die from uncontrolled exsanguination along with rapidly evolving hemostatic failure. This review highlights the most recent advances in the field and provides an outline for future research directions.
RECENT FINDINGS: The updated definition of NCTH includes a combination of high-grade anatomical torso injury, hemodynamic instability, urgent need for hemorrhage control and aggressive hemostatic resuscitation. Therapeutic concepts consider the following three aspects: control the bleeding source (close the tap), resuscitate to maintain organ perfusion and restore hemostasis (fill the tank), and increase the body's resistance against ischemia (upgrade the armor).
SUMMARY: The concepts for the early management of NCTH have substantially evolved over the last decade. The development of new devices and techniques combined with early intervention of hemostatic failure have contributed to more successful resuscitations. Future research needs to refine and validate their potential clinical application.
ADHD in adulthood, with an estimated prevalence of 2 - 3 %, is associated with challenges in daily life functioning. The availability of evidence-based psychological interventions for adults with ADHD is poor. Interventions delivered over the Internet might help to increase the availability of effective psychological interventions for this group. The primary aim of this study is to examine the efficacy of a self-guided Internet-delivered intervention for coping with ADHD. The secondary aim is to investigate the effects of individual adaptation of the intervention on adherence, satisfaction and clinical outcomes. A minimum of 118 participants with a self-reported ADHD diagnosis will be included in the study. In phase 1 we will conduct a randomized controlled trial with two arms, 1) self-guided Internet-delivered intervention for coping with ADHD (N=59), 2) self-guided online psychoeducation (control group, N= 59), with a 3 month follow-up. After 3 months the second phase of the study starts. In this phase (II) the control group participants will receive an adaptive version of the Internet-delivered intervention. This includes adaptation of the order of the modules to the individual participant needs, with the use of rule-based and machine-learning based adaptation. Clinical outcomes in both phases are inattention, hyperactivity, quality of life and stress. Uptake, usage, adherence and satisfaction will be explored. Repeated measurers are at baseline, weekly during the intervention period, post-intervention and 3 months follow-up.
The safety and efficacy of REVATIO have been established in pediatric patients 1 to 17 years old, for the treatment of PAH (WHO Group I) to improve exercise ability and, in patients too young to perform standard exercising testing, pulmonary hemodynamics thought to underlie improvements in exercise. Use of REVATIO for this indication is supported by evidence from adequate and well-controlled studies in adults with additional PK and safety data in pediatric patients aged 1 year and older [see Adverse Reactions (6.1), Clinical Studies (14)]. The safety and effectiveness of REVATIO have not been established in pediatric patients younger than 1 year of age. 

During the conduct of the pediatric studies (STARTS-1 and STARTS-2) [see Clinical Studies (14)], an imbalance in the number of deaths was noted: 5/55 (9.1%), 10/74 (13.5%), and 22/100 (22%) in the sildenafil low, medium, and high dose groups, respectively. The causes of death were related to the progression of PAH. This safety observation in pediatrics was not confirmed in a study conducted in adults designed to evaluate this risk (Study A1481324). Given the beneficial effects on clinical worsening and death observed in adults with increasing doses (Study A1481324) and the expected similarity of disease in pediatrics and adults, a causal association for the observed dose-related effect on mortality in pediatric patients is unlikely, and therefore, the available data support dosing in pediatric patients > 45 kg up to a maximum of 40 mg three times a day.
FIELD: medicine; wide-spectrum preparation. SUBSTANCE: proposed composition made in the form of ointment has products of animal, vegetable, and mineral origin. Balsamic ointment "PANATSEYA" eliminates retro-virus infections and resolves tumor masses of lymphatic system by destroying or transporting them from infection focus in patients ill with AIDS (brain lymphomas, lymphadenitis, sarcoma, etc.) including reversibility of recovery processes; at the same time it is excellent prophylactic means for treatment of accompanying diseases of systematic spectrum. Balsamic ointment "PANATSEYA" may be used to precancer and cancer treatment. Its therapeutic effect is not lost with time, there are no analogs to this medicament, and it may be used for patients of all ages including pregnant women and infants. EFFECT: enlarged functional capabilities.
Spliceosomal GTPase elongation factor Tu GTP binding domain containing 2 (EFTUD2) is a causative gene for mandibulofacial dysostosis with microcephaly (MFDM) syndrome comprising cerebellar hypoplasia and motor dysfunction. How EFTUD2 deficiency contributes to these symptoms remains elusive. Here, we demonstrate that specific ablation of Eftud2 in cerebellar Purkinje cells (PCs) in mice results in severe ferroptosis, PC degeneration, dyskinesia, and cerebellar atrophy, which recapitulates phenotypes observed in patients with MFDM. Mechanistically, Eftud2 promotes Scd1 and Gch1 expression, upregulates monounsaturated fatty acid phospholipids, and enhances antioxidant activity, thereby suppressing PC ferroptosis. Importantly, we identified transcription factor Atf4 as a downstream target to regulate anti-ferroptosis effects in PCs in a p53-independent manner. Inhibiting ferroptosis efficiently rescued cerebellar deficits in Eftud2 cKO mice. Our data reveal an important role of Eftud2 in maintaining PC survival, showing that pharmacologically or genetically inhibiting ferroptosis may be a promising therapeutic strategy for EFTUD2 deficiency-induced disorders.
A method and compositions for inhibiting excessive scar formation and adhesions by administering to a patient in need thereof an effective amount of an angiogenesis inhibitor. In the preferred embodiment, the angiogenesis inhibitor is selective, such as a fumagillol derivative like 0-chloroacetylcarbamoyl-Fumagillol (TNP-470, TAP Pharmaceuticals), thalidomide, or a selective drug having more than one activity, such as minocycline or penicilliamine which also have antibiotic activity. Less selective compounds can also be used, such as the cytokine IL12. Patients to be treated include those having experienced trauma, surgical intervention, burns, and other types of injuries. The inhibitor is administered in an amount effective to decrease excessive scarring, defined as formation of high density tissue including cells and connective tissue, without preventing normal wound closure. The inhibitors can be administered systemically and/or locally or topically, as needed. For prevention of adhesions, the angiogenesis inhibitor would typically be applied at the time of surgery, preferably in a controlled release formulation and/or using barrier technology.
The present invention relates to a preparing process for compound spanishneedles ointment of a Chinese drug preparation, which uses a medicinal material of spanishneedles herb of a Taishan Mount special product as main medicine. Scutellaria root, coptis, phellodendron, earthworm and sesame oil serve as substrate in an auxiliary mode, and beeswax serves as excipient. The spanishneedles herb is boiled by adding water, and decoction liquid is concentrated. After sesame oil is refined, other medicinal materials are added and heated by soft fire, and dregs of decoction is discarded after filtration to obtain filtering oil. The compound spanishneedles ointment is made through the processes of merging decoction liquid, heating the filtering oil by soft fire until no water exists, homogenizing by adding beeswax, etc. The present invention has the advantages of rich medicinal herbs resource, low cost, easy acquirement and simple manufacturing process. The present invention is widely used for treating diseases of burn and scald, open type skin injury, bedsore, chronic infection wounds, body surface or mucosa chronic canker, etc. The present invention has combined curative effect of promoting blood circulation for removing blood stasis, clearing heat, removing toxicity, eliminating slough and promoting granulation.
BACKGROUND: Obstructive sleep apnea (OSA) affects 10-26% of adults in the United States with known sex differences in prevalence and severity. OSA is characterized by elevated inflammation, oxidative stress (OS), and cognitive dysfunction. However, there is a paucity of data regarding the role of sex in the OSA phenotype. Prior findings suggest women exhibit different OSA phenotypes than men, which could result in under-reported OSA prevalence in women. To examine the relationship between OSA and sex, we used chronic intermittent hypoxia (CIH) to model OSA in rats. We hypothesized that CIH would produce sex-dependent phenotypes of inflammation, OS, and cognitive dysfunction, and these sex differences would be dependent on mitochondrial oxidative stress (mtOS).
METHODS: Adult male and female Sprague Dawley rats were exposed to CIH or normoxia for 14 days to examine the impact of sex on CIH-associated circulating inflammation (IL-1β, IL-6, IL-10, TNF-α), circulating steroid hormones, circulating OS, and behavior (recollective and spatial memory; gross and fine motor function; anxiety-like behaviors; and compulsive behaviors). Rats were implanted with osmotic minipumps containing either a mitochondria-targeting antioxidant (MitoTEMPOL) or saline vehicle 1 week prior to CIH initiation to examine how inhibiting mtOS would affect the CIH phenotype.
RESULTS: Sex-specific differences in CIH-induced inflammation, OS, motor function, and compulsive behavior were observed. In female rats, CIH increased inflammation (plasma IL-6 and IL-6/IL-10 ratio) and impaired fine motor function. Conversely, CIH elevated circulating OS and compulsivity in males. These sex-dependent effects of CIH were blocked by inhibiting mtOS. Interestingly, CIH impaired recollective memory in both sexes but these effects were not mediated by mtOS. No effects of CIH were observed on spatial memory, gross motor function, or anxiety-like behavior, regardless of sex.
CONCLUSIONS: Our results indicate that the impact of CIH is dependent on sex, such as an inflammatory response and OS response in females and males, respectively, that are mediated by mtOS. Interestingly, there was no effect of sex or mtOS in CIH-induced impairment of recollective memory. These results indicate that mtOS is involved in the sex differences observed in CIH, but a different mechanism underlies CIH-induced memory impairments.
Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a "five A's cycle" counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks.
BACKGROUND: As a rare endocrine disorder, Cushing's Syndrome (Cushing's) is characterized by numerous symptoms and a non-specific presentation, leading to a delay to diagnosis for patients with this disease. To date, research examining the lived experiences of patients with Cushing's in healthcare is absent in the literature. This preliminary inquiry into the healthcare experiences of women with Cushing's aimed to examine the utility of this line of inquiry to support the patient centered care of individuals with Cushing's.
METHODS: Seven women from across Canada with endogenous Cushing's participated in the study. Semi-structured interviews were conducted examining participants' healthcare and body-related experiences with Cushing's. Results pertaining to healthcare experiences were analyzed for the current study using reflexive thematic analysis.
RESULTS: Four themes emerged whereby women with Cushing's experienced (1) a lack of patient centered care, characterized by provider miscommunication and medical gaslighting; (2) a misunderstanding of their symptoms as related to weight gain; (3) weight stigma in healthcare encounters; and (4) a shift in their quality of care following diagnosis.
CONCLUSIONS: The results highlight the importance of patient centered care as well as the negative impact of commonly reported barriers to patient centered care. Cushing's specific barriers to patient centered care may include weight stigma as well as the rare incidence of Cushing's. Further research is needed to better understand the healthcare experiences of people with Cushing's in Canada.
The body has defensive responses to correct low blood sugar (hypoglycemia). A vital component of this response is release of glucagon and activation of the sympathetic nervous system, which provides the means for raising blood glucose levels towards normal. We can measure circulating hormones indicating the level of these responses, but additionally, sympathetic nervous system responses can be measured directly. We can measure the sympathetic nerve activity that controls blood flow to muscles (MSNA) and blood flow and sweating to skin (SSNA). The purpose of this study is to determine if either hypoglycemia or exercise cause differential responses in muscle and skin sympathetic nerve activity. We would also like to determine what the sympathetic response is to cycling exercise with insulin and normal blood sugar. Therefore, we would like to test the sympathetic responses to insulin with normal blood glucose, hypoglycemia, and during exercise bouts and normal blood glucose, with or without insulin.
Patients receive paclitaxel albumin-stabilized nanoparticle formulation (Abraxane®) IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.